Acute coronary syndrome induced by capecitabine therapy
| Autor: | Namal Wijesinghe, Paul I. Thompson, Hugh McAlister |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Pulmonary and Respiratory Medicine
Drug Oncology medicine.medical_specialty Acute coronary syndrome Antimetabolites Antineoplastic Side effect media_common.quotation_subject Coronary Disease Coronary Angiography Deoxycytidine Capecitabine Diagnosis Differential chemistry.chemical_compound Electrocardiography Internal medicine medicine Humans Prodrugs Adverse effect media_common Cardiotoxicity business.industry Middle Aged medicine.disease chemistry Fluorouracil Colonic Neoplasms Female Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Heart, lungcirculation. 15(5) |
| ISSN: | 1443-9506 |
| Popis: | Capecitabine, a new member of the fluoropyrimidine family, is an orally administered drug that delivers fluorouracil (5-FU) selectively to the tumour. Although the cardiotoxicity of 5-FU is well documented, there is little published data about cardiovascular adverse effects of Capecitabine. This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect